June 3rd 2025
A PRO analysis showed that darolutamide plus ADT improved HRQOL outcomes vs placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer.
June 2nd 2025
In the VERIFY study, rusfertide significantly improved clinical responses vs placebo in polycythemia vera, offering a potential new therapy.
June 1st 2025
Adjuvant nivolumab generated durable DFS and DMFS outcomes in resectable esophageal or GEJ cancer.
TTFields plus chemotherapy improved overall survival in unresectable, locally advanced pancreatic ductal adenocarcinoma.
May 31st 2025
Nivolumab plus ipilimumab displayed superior PFS and PFS2 data vs chemotherapy and nivolumab monotherapy in mismatch repair-deficient colorectal cancer.
May 22nd 2025
AI-assisted training of pathologists enhanced the accuracy of HER2 IHC scoring, potentially expanding eligibility for HER2-targeted treatments.
April 30th 2025
First-line adagrasib monotherapy demonstrated preliminary efficacy and tolerability in patients with SK11- and KRAS G12C–mutant NSCLC.
April 29th 2025
Updated findings from a phase 2 study investigating the IL-2–binding monoclonal antibody AU-007 show a manageable safety profile with antitumor evidence.
April 28th 2025
A retrospective analysis showed higher response rate for cabozantinib/nivolumab vs. lenvatinib/pembrolizumab in advanced RCC.
April 26th 2025
Enfortumab vedotin plus pembrolizumab followed by surgery led to high CR rates in advanced urothelial cancer.
December 29th 2024
Beyond a lengthy list of accomplishments across the leukemia spectrum of treatment, Garcia-Manero holds the importance of mentorship as incredibly dear to his heart and a way to pass the torch forward in cancer care.
October 2nd 2024
Dual HER2 blockade with trastuzumab plus pertuzumab may serve as an effective option for hormone receptor–positive, HER2-positive metastatic breast cancer.
September 30th 2024
All patients with relapsed/refractory multiple myeloma experienced a response when treated with anitocabtagene autoleucel in a phase 1 trial.
Durcabtagene autoleucel generated responses with a tolerable safety profile in relapsed/refractory multiple myeloma.
September 16th 2024
Tremelimumab plus durvalumab sustained an overall survival improvement in unresectable hepatocellular carcinoma.
September 15th 2024
Encorafenib, cetuximab, and FOLFIRI demonstrate promising antitumor activity in patients with BRAF V600E-mutant metastatic colorectal cancer.
September 14th 2024
First-line combinations with trastuzumab deruxtecan showed initial efficacy in HER2-positive esophageal, gastric, and gastroesophageal junction cancers.
September 5th 2024
The investigation of treatments harnessing the immune system in patients with T-cell lymphoma could lead to "a new era" of therapy for this patient population.
June 14th 2024
Over a 4-year period, most patients with lower-risk myelofibrosis experienced disease progression, according to the prospective MOST study.
May 3rd 2024
Apalutamide and ADT elicited a 100% biochemical recurrence-free survival rate at 24 months in high-risk localized prostate cancer following radical prostatectomy.